$50 million being "chump change" in bio is really the point here. Even any valid cancer patent is worth 10x+ that amount, and the company has more than 20. The collateral this company has dwarfs that amount. It is not if, but when the money shows up. A bio with hundreds of billions in market cap spends more than that on copy paper.